An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in lupus

Journal of Immunology

Volumn 187, Issue 7, 2011, Pages 3888-3894

  Ahuja, Anupama ^a   Teichmann, Lino L ^a   Wang, Haowei ^a   Dunn, Robert ^b   Kehry, Marilyn R ^b   Shlomchik, Mark J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR ANTIBODY; CD20 ANTIBODY; CYTOKINE ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE DEPLETION; CELL SELECTION; CELL SURVIVAL; CONTROLLED STUDY; IMMUNOGLOBULIN BLOOD LEVEL; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; CELL SEPARATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; MICE, INBRED MRL LPR; MICE, TRANSGENIC; PHAGOCYTOSIS;

EID: 80053527529     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101629     Document Type: Article

References (47)

1. Martin, F., and A. C. Chan. 2006. B cell immunobiology in disease: evolving concepts from the clinic. Annu. Rev. Immunol. 24: 467-496.
2. Browning, J. L. 2006. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat. Rev. Drug Discov. 5: 564-576. (Pubitemid 43971191)
3. Chan, O. T., M. P. Madaio, and M. J. Shlomchik. 1999. B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J. Immunol. 163: 3592-3596. (Pubitemid 29450878)
4. Shlomchik, M. J., M. P. Madaio, D. Ni, M. Trounstein, and D. Huszar. 1994. The role of B cells in lpr/lpr-induced autoimmunity. J. Exp. Med. 180: 1295-1306. (Pubitemid 24289603)
5. Looney, R. J. 2005. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis. Rheumatology (Oxford) 44(Suppl. 2): ii13-ii17.
6. Merrill, J. T., C. M. Neuwelt, D. J. Wallace, J. C. Shanahan, K. M. Latinis, J. C. Oates, T. O. Utset, C. Gordon, D. A. Isenberg, H.-J. Hsieh, et al. 2010. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62: 222-233.
7. Sanz, I., and F. E. Lee. 2010. B cells as therapeutic targets in SLE. Nat. Rev. Rheumatol. 6: 326-337.
8. Chan, O. T. M., M. P. Madaio, and M. J. Shlomchik. 1999. The central and multiple roles of B cells in lupus pathogenesis. Immunol. Rev. 169: 107-121. (Pubitemid 29338727)
9. Gong, Q., Q. Ou, S. Ye, W. P. Lee, J. Cornelius, L. Diehl, W. Y. Lin, Z. Hu, Y. Lu, Y. Chen, et al. 2005. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174: 817-826. (Pubitemid 40094277)
10. Ahuja, A., J. Shupe, R. Dunn, M. Kashgarian, M. R. Kehry, and M. J. Shlomchik. 2007. Depletion of B cells in murine lupus: efficacy and resistance. J. Immunol. 179: 3351-3361.
11. Uchida, J., Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199: 1659-1669. (Pubitemid 38821999)
12. Li, Y., F. Chen, M. Putt, Y. K. Koo, M. Madaio, J. C. Cambier, P. L. Cohen, and R. A. Eisenberg. 2008. B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice. J. Immunol. 181: 2961-2972.
13. Bekar, K. W., T. Owen, R. Dunn, T. Ichikawa, W. Wang, R. Wang, J. Barnard, S. Brady, S. Nevarez, B. I. Goldman, et al. 2010. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 62: 2443-2457.
14. Xiu, Y., C. P. Wong, J. D. Bouaziz, Y. Hamaguchi, Y. Wang, S. M. Pop, R. M. Tisch, and T. F. Tedder. 2008. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotypespecific differences in FcgR effector functions. J. Immunol. 180: 2863-2875.
15. Looney, R. J., J. H. Anolik, D. Campbell, R. E. Felgar, F. Young, L. J. Arend, J. A. Sloand, J. Rosenblatt, and I. Sanz. 2004. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50: 2580-2589. (Pubitemid 39062719)
16. Anolik, J. H., J. Barnard, T. Owen, B. Zheng, S. Kemshetti, R. J. Looney, and I. Sanz. 2007. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 56: 3044-3056. (Pubitemid 47502752)
17. Sfikakis, P. P., J. N. Boletis, and G. C. Tsokos. 2005. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr. Opin. Rheumatol. 17: 550-557. (Pubitemid 41527814)
18. Walport, M. J. 2000. Lupus, DNase and defective disposal of cellular debris. Nat. Genet. 25: 135-136. (Pubitemid 30394978)
19. Chen, J., M. Trounstine, F. W. Alt, F. Young, C. Kurahara, J. F. Loring, and D. Huszar. 1993. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int. Immunol. 5: 647-656. (Pubitemid 23209419)
20. Chan, O. T., L. G. Hannum, A. M. Haberman, M. P. Madaio, and M. J. Shlomchik. 1999. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189: 1639-1648.
21. Clark, E. A., G. Shu, and J. A. Ledbetter. 1985. Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc. Natl. Acad. Sci. USA 82: 1766-1770. (Pubitemid 15085258)
22. Christensen, S. R., M. Kashgarian, L. Alexopoulou, R. A. Flavell, S. Akira, and M. J. Shlomchik. 2005. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202: 321-331. (Pubitemid 41043827)
23. Shlomchik, M. J., D. Zharhary, T. Saunders, S. A. Camper, and M. G. Weigert. 1993. A rheumatoid factor transgenic mouse model of autoantibody regulation. Int. Immunol. 5: 1329-1341. (Pubitemid 23308094)
24. Merrill, J. T., and J. P. Buyon. 2010. Rituximab: wanted dead or alive.... Arthritis Rheum. 62: 2188-2191.
25. Lövgren, T., M. L. Eloranta, U. Ba° ve, G. V. Alm, and L. Rönnblom. 2004. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 50: 1861-1872. (Pubitemid 38725099)
26. Boulé, M. W., C. Broughton, F. Mackay, S. Akira, A. Marshak-Rothstein, and I. R. Rifkin. 2004. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199: 1631-1640. (Pubitemid 38821996)
27. Kaneko, Y., F. Nimmerjahn, and J. V. Ravetch. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673. (Pubitemid 44201145)
28. Wofsy, D., and W. E. Seaman. 1987. Reversal of advanced murine lupus in NZB/ NZW F1 mice by treatment with monoclonal antibody to L3T4. J. Immunol. 138: 3247-3253. (Pubitemid 17071900)
29. Vos, K., R. M. Thurlings, C. A.Wijbrandts, D. Van Schaardenburg, D. M. Gerlag, and P. P. Tak. 2007. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum. 56: 772-778. (Pubitemid 46399424)
30. Dass, S., A. C. Rawstron, E. M. Vital, K. Henshaw, D. McGonagle, and P. Emery. 2008. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 58: 2993-2999.
31. Frank, M. M., M. I. Hamburger, T. J. Lawley, R. P. Kimberly, and P. H. Plotz. 1979. Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N. Engl. J. Med. 300: 518-523. (Pubitemid 9167825)
32. Russell, P. J., and A. D. Steinberg. 1983. Studies of peritoneal macrophage function in mice with systemic lupus erythematosus: depressed phagocytosis of opsonized sheep erythrocytes in vitro. Clin. Immunol. Immunopathol. 27: 387-402. (Pubitemid 13081093)
33. Anolik, J. H., D. Campbell, R. E. Felgar, F. Young, I. Sanz, J. Rosenblatt, and R. J. Looney. 2003. The relationship of FcgRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48: 455-459. (Pubitemid 36278014)
34. Albert, D., J. Dunham, S. Khan, J. Stansberry, S. Kolasinski, D. Tsai, S. Pullman- Mooar, F. Barnack, C. Striebich, R. J. Looney, et al. 2008. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann. Rheum. Dis. 67: 1724-1731.
35. Sutter, J. A., J. Kwan-Morley, J. Dunham, Y.-Z. Du, M. Kamoun, D. Albert, R. A. Eisenberg, and E. T. Luning Prak. 2008. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin. Immunol. 126: 282-290.
36. Baumann, I., W. Kolowos, R. E. Voll, B. Manger, U. Gaipl, W. L. Neuhuber, T. Kirchner, J. R. Kalden, and M. Herrmann. 2002. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum. 46: 191-201. (Pubitemid 34121664)
37. Tas, S. W., P. Quartier, M. Botto, and L. Fossati-Jimack. 2006. Macrophages from patients with SLE and rheumatoid arthritis have defective adhesion in vitro, while only SLE macrophages have impaired uptake of apoptotic cells. Ann. Rheum. Dis. 65: 216-221. (Pubitemid 43131996)
38. Gaipl, U. S., L. E. Munoz, G. Grossmayer, K. Lauber, S. Franz, K. Sarter, R. E. Voll, T. Winkler, A. Kuhn, J. Kalden, et al. 2007. Clearance deficiency and systemic lupus erythematosus (SLE). J. Autoimmun. 28: 114-121. (Pubitemid 46680499)
39. Steinbach, F., F. Henke, B. Krause, B. Thiele, G. R. Burmester, and F. Hiepe. 2000. Monocytes from systemic lupus erythematous patients are severely altered in phenotype and lineage flexibility. Ann. Rheum. Dis. 59: 283-288. (Pubitemid 30305570)
40. Potter, P. K., J. Cortes-Hernandez, P. Quartier, M. Botto, and M. J. Walport. 2003. Lupus-prone mice have an abnormal response to thioglycolate and an impaired clearance of apoptotic cells. J. Immunol. 170: 3223-3232. (Pubitemid 36302200)
41. Kanno, H., O. Tachiwaki, M. Nose, and M. Kyogoku. 1994. Immune complexdegradation ability of macrophages in MRL/Mp-lpr/lpr lupus mice and its regulation by cytokines. Clin. Exp. Immunol. 95: 115-121. (Pubitemid 24207113)
42. Dang-Vu, A. P., D. S. Pisetsky, and J. B. Weinberg. 1987. Functional alterations of macrophages in autoimmune MRL-lpr/lpr mice. J. Immunol. 138: 1757-1761. (Pubitemid 17040798)
43. Pritchard, N. R., A. J. Cutler, S. Uribe, S. J. Chadban, B. J. Morley, and K. G. Smith. 2000. Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcgRII. Curr. Biol. 10: 227-230. (Pubitemid 30146790)
44. Ramanujam, M., X. Wang, W. Huang, L. Schiffer, C. Grimaldi, A. Akkerman, B. Diamond, M. P. Madaio, and A. Davidson. 2004. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J. Immunol. 173: 3524-3534. (Pubitemid 39142063)
45. Ferraro, A. J., M. T. Drayson, C. O. Savage, and I. C. MacLennan. 2008. Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab. Eur. J. Immunol. 38: 292-298.
46. Jacobi, A. M., H. Mei, B. F. Hoyer, I. M. Mumtaz, K. Thiele, A. Radbruch, G. R. Burmester, F. Hiepe, and T. Dörner. 2010. HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 69: 305-308.
47. Maloney, D. G. 1999. Preclinical and phase I and II trials of rituximab. Semin. Oncol. 26(Suppl. 14): 74-78. (Pubitemid 29523414)